Latest Health News

Anagenics has delivered a significant financial turnaround in FY25, driven by a strategic restructure, exiting loss-making operations, and securing new royalty agreements. Despite a revenue dip, the company improved profitability and cash flow, positioning itself for sustainable growth.

FINEOS Corporation delivered solid first-half results with revenue growth and improved profitability, while navigating currency challenges that temper full-year guidance.

FINEOS Corporation Holdings PLC reports solid half-year growth with rising subscription revenue and improved margins, while navigating currency challenges. The company remains confident in achieving positive free cash flow for FY25 and advancing its AI and cloud strategies.

FINEOS Corporation Holdings plc reported a 4.2% increase in revenue to €67.1 million for H1 2025, alongside a significant 76% reduction in losses, driven by subscription growth and operational efficiencies.

Solvar Limited reported a notable 84.4% jump in net profit for FY25 even as revenue declined 6.1%, alongside a healthy dividend increase.

SPC Global Holdings Ltd has reported FY25 proforma results exceeding guidance with a normalised EBITDA of $30.3 million, setting the stage for ambitious growth and international expansion in FY26.

Resimac Group Ltd delivered a robust FY25 performance, marked by strong organic growth in home loans and asset finance, bolstered by the strategic acquisition of Westpac's $1.5 billion auto portfolio. The company raised dividends to 19 cents fully franked, reflecting confidence amid rising impairment expenses.

Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.

Farm Pride Foods Ltd has reported a remarkable 384% increase in net profit for the financial year ending June 2025, despite revenues remaining virtually unchanged. The company’s financial health shows signs of strengthening, though no dividends were declared.

Vitasora Health reported a sharp rise in losses and operating cash outflows for FY2025, despite achieving significant cost savings from its Orb Health acquisition. The company faces a material uncertainty over its ability to continue as a going concern.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.